Gene editing is now a medical reality – Sickle Cell CRISPR treatment approved by FDA

In the U.S., sickle cell disease disproportionately affects Black patients, who have historically faced discrimination and barriers to healthcare. CRISPR, a groundbreaking gene editing technology, holds promise for treating the disease, but ethical concerns and regulatory frameworks need to be addressed. However, Artificial Intelligence (AI) can help mitigate risks associated with gene editing, as it provides advanced processing capabilities for understanding the impacts of gene editing and enables personalized treatments.